Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways.

Steele CD, Tarabichi M, Oukrif D, Webster AP, Ye H, Fittall M, Lombard P, Martincorena I, Tarpey PS, Collord G, Haase K, Strauss SJ, Berisha F, Vaikkinen H, Dhami P, Jansen M, Behjati S, Amary MF, Tirabosco R, Feber A, Campbell PJ, Alexandrov LB, Van Loo P, Flanagan AM, Pillay N.

Cancer Cell. 2019 Mar 18;35(3):441-456.e8. doi: 10.1016/j.ccell.2019.02.002.

2.

Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma.

Cheng L, Pandya PH, Liu E, Chandra P, Wang L, Murray ME, Carter J, Ferguson M, Saadatzadeh MR, Bijangi-Visheshsaraei K, Marshall M, Li L, Pollok KE, Renbarger JL.

BMC Med Genomics. 2019 Jan 31;12(Suppl 1):23. doi: 10.1186/s12920-018-0456-5.

3.

Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas.

Cancer Genome Atlas Research Network. Electronic address: elizabeth.demicco@sinaihealthsystem.ca; Cancer Genome Atlas Research Network.

Cell. 2017 Nov 2;171(4):950-965.e28. doi: 10.1016/j.cell.2017.10.014.

4.

Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics.

Pérot G, Chibon F, Montero A, Lagarde P, de Thé H, Terrier P, Guillou L, Ranchère D, Coindre JM, Aurias A.

Am J Pathol. 2010 Oct;177(4):2080-90. doi: 10.2353/ajpath.2010.100104.

5.

Single cell genomics reveals activation signatures of endogenous SCAR's networks in aneuploid human embryos and clinically intractable malignant tumors.

Glinsky GV.

Cancer Lett. 2016 Oct 10;381(1):176-93. doi: 10.1016/j.canlet.2016.08.001. Epub 2016 Aug 3.

PMID:
27497790
6.

MET gene copy number alterations and expression of MET and hepatocyte growth factor are potential biomarkers in angiosarcomas and undifferentiated pleomorphic sarcomas.

Schmitz K, Koeppen H, Binot E, Fassunke J, Künstlinger H, Ihle MA, Heydt C, Wardelmann E, Büttner R, Merkelbach-Bruse S, Rüschoff J, Schildhaus HU.

PLoS One. 2015 Apr 6;10(4):e0120079. doi: 10.1371/journal.pone.0120079. eCollection 2015.

7.

Ploidy-Seq: inferring mutational chronology by sequencing polyploid tumor subpopulations.

Malhotra A, Wang Y, Waters J, Chen K, Meric-Bernstam F, Hall IM, Navin NE.

Genome Med. 2015 Jan 28;7(1):6. doi: 10.1186/s13073-015-0127-5. eCollection 2015.

8.

Genome-wide methylation profiling and copy number analysis in atypical fibroxanthomas and pleomorphic dermal sarcomas indicate a similar molecular phenotype.

Koelsche C, Stichel D, Griewank KG, Schrimpf D, Reuss DE, Bewerunge-Hudler M, Vokuhl C, Dinjens WNM, Petersen I, Mittelbronn M, Cuevas-Bourdier A, Buslei R, Pfister SM, Flucke U, Mechtersheimer G, Mentzel T, von Deimling A.

Clin Sarcoma Res. 2019 Feb 14;9:2. doi: 10.1186/s13569-019-0113-6. eCollection 2019.

9.

Conservation of immune gene signatures in solid tumors and prognostic implications.

Chifman J, Pullikuth A, Chou JW, Bedognetti D, Miller LD.

BMC Cancer. 2016 Nov 22;16(1):911.

10.

Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers.

Cohen AL, Piccolo SR, Cheng L, Soldi R, Han B, Johnson WE, Bild AH.

BMC Med Genomics. 2013 Sep 30;6:35. doi: 10.1186/1755-8794-6-35.

11.

Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.

Ashley CW, Da Cruz Paula A, Kumar R, Mandelker D, Pei X, Riaz N, Reis-Filho JS, Weigelt B.

Gynecol Oncol. 2019 Jan;152(1):11-19. doi: 10.1016/j.ygyno.2018.10.032. Epub 2018 Nov 8.

PMID:
30415991
12.

Coincident expression of beta-catenin and cyclin D1 in endometrial stromal tumors and related high-grade sarcomas.

Kurihara S, Oda Y, Ohishi Y, Kaneki E, Kobayashi H, Wake N, Tsuneyoshi M.

Mod Pathol. 2010 Feb;23(2):225-34. doi: 10.1038/modpathol.2009.162. Epub 2009 Nov 6.

13.

Case Report: Exome sequencing reveals recurrent RETSAT mutations and a loss-of-function POLDIP2 mutation in a rare undifferentiated tongue sarcoma.

Chan JYK, Poon PHY, Zhang Y, Ng CWK, Piao WY, Ma M, Yip KY, Chan ABW, Lui VWY.

F1000Res. 2018 Apr 26;7:499. doi: 10.12688/f1000research.14383.1. eCollection 2018.

14.

Targeted next-generation sequencing of CIC-DUX4 soft tissue sarcomas demonstrates low mutational burden and recurrent chromosome 1p loss.

Lazo de la Vega L, Hovelson DH, Cani AK, Liu CJ, McHugh JB, Lucas DR, Thomas DG, Patel RM, Tomlins SA.

Hum Pathol. 2016 Dec;58:161-170. doi: 10.1016/j.humpath.2016.09.004. Epub 2016 Sep 21.

15.

Multiregion human bladder cancer sequencing reveals tumour evolution, bladder cancer phenotypes and implications for targeted therapy.

Heide T, Maurer A, Eipel M, Knoll K, Geelvink M, Veeck J, Knuechel R, van Essen J, Stoehr R, Hartmann A, Altmueller J, Graham TA, Gaisa NT.

J Pathol. 2019 Feb 4. doi: 10.1002/path.5250. [Epub ahead of print]

PMID:
30719704
16.

Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies.

Berg KCG, Eide PW, Eilertsen IA, Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA, Eknæs M, Lind GE, Myklebost O, Skotheim RI, Sveen A, Lothe RA.

Mol Cancer. 2017 Jul 6;16(1):116. doi: 10.1186/s12943-017-0691-y.

17.

Mutational spectra and mutational signatures: Insights into cancer aetiology and mechanisms of DNA damage and repair.

Phillips DH.

DNA Repair (Amst). 2018 Nov;71:6-11. doi: 10.1016/j.dnarep.2018.08.003. Epub 2018 Aug 24. Review.

18.

Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data.

Wang E, Zaman N, Mcgee S, Milanese JS, Masoudi-Nejad A, O'Connor-McCourt M.

Semin Cancer Biol. 2015 Feb;30:4-12. doi: 10.1016/j.semcancer.2014.04.002. Epub 2014 Apr 18. Review.

PMID:
24747696
19.

Histologic and Immunohistochemical Analyses of Soft Tissue Sarcomas From brca2-Mutant/ tp53-Mutant Zebrafish Are Consistent With Neural Crest (Schwann Cell) Origin.

White LA, Sexton JM, Shive HR.

Vet Pathol. 2017 Mar;54(2):320-327. doi: 10.1177/0300985816669406. Epub 2016 Nov 24.

PMID:
27879444
20.

PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma.

Budczies J, Mechtersheimer G, Denkert C, Klauschen F, Mughal SS, Chudasama P, Bockmayr M, Jöhrens K, Endris V, Lier A, Lasitschka F, Penzel R, Dietel M, Brors B, Gröschel S, Glimm H, Schirmacher P, Renner M, Fröhling S, Stenzinger A.

Oncoimmunology. 2017 Jan 27;6(3):e1279777. doi: 10.1080/2162402X.2017.1279777. eCollection 2017.

Supplemental Content

Support Center